Medical condition
Cancer
Cancer is a medical condition tracked by NovaPharmaNews across 12 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- zanidatamab (ZIIHERA) Antineoplastic and immunomodulating agents (L01)
- topotecan (HYCAMTIN) Antineoplastic and immunomodulating agents (L01)
- tislelizumab (TEVIMBRA) Antineoplastic and immunomodulating agents (L01)
- mobocertinib (EXKIVITY) Antineoplastic and immunomodulating agents (L01)
- ibandronic acid (IBANDRONIC ACID SANDOZ) Musculo-skeletal system (M05)
- human igg1 monoclonal antibody specific for human interleukin-1 alpha (HUMAN IGG1 MONOCLONAL ANTIBODY SPECIFIC FOR HUMAN INTERLEUKIN-1 ALPHA XBIOTECH) Antineoplastic and immunomodulating agents (L01)
- etirinotecan pegol (ONZEALD) Antineoplastic and immunomodulating agents (L01)
- epoetin theta (EPORATIO) Blood and blood forming organs (B03)
- cemiplimab (LIBTAYO) Antineoplastic and immunomodulating agents (L01)
- pralsetinib (GAVRETO) Antineoplastic and immunomodulating agents (L01)
- paclitaxel (PACLITAXEL ACCORD) Antineoplastic and immunomodulating agents (L01)
- nintedanib (OFEV) Antineoplastic and immunomodulating agents (L01)
Latest Cancer news
BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial
BioNTech and Genentech have dosed the first patient in the Phase 1 pancreatic cancer mRNA vaccine trial of autogene cevumeran. Earlier Nature data showed immune responses in 8 of 16 patients and established the study as the first mRNA vaccine trial in pancreatic cancer.
EMA backs datopotamab deruxtecan, but lung cancer access remains unclear
EMA recommended datopotamab deruxtecan in Europe, but the supported EU approval in the evidence base is for HR-positive, HER2-negative breast cancer rather than lung cancer. In the U.S., DATROWAY has accelerated approval for EGFR-mutated NSCLC, making this a key catalyst-tracking update for BD teams and investors.
EMA backs datopotamab deruxtecan for advanced lung cancer
EMA action on datopotamab deruxtecan adds a key catalyst for lung cancer tracking, even as the program’s regulatory path differs by region. For BD teams, investors, and analysts, the story now centers on approval status, label scope, and the next clinical and filing milestones.
FDA approves Vyloy for HER2-negative gastric and GEJ cancer
The FDA approved zolbetuximab-clzb (Vyloy) with chemotherapy for gastric and gastroesophageal junction adenocarcinoma on October 18, 2024. Astellas says it is the first and only CLDN18.2-targeted therapy approved in the U.S. for these cancers.
FDA approves Keytruda for adjuvant NSCLC treatment, expanding Merck’s lung cancer label
The FDA approved pembrolizumab (Keytruda) for adjuvant treatment of stage IB, II, and IIIA non-small cell lung cancer after resection and platinum chemotherapy. For Merck and investors, the key readout is how this label expansion may shape lung cancer franchise momentum and future catalyst tracking.
AstraZeneca and Daiichi Sankyo datopotamab deruxtecan hits lung cancer endpoint
AstraZeneca and Daiichi Sankyo datopotamab deruxtecan met the dual primary endpoint of progression-free survival in TROPION-Lung01, strengthening the program’s clinical case in advanced NSCLC. The readout matters for investors and BD teams because it arrives alongside an FDA-labeled EGFR-mutated NSCLC indication and a mixed breast cancer survival backdrop.
FDA approves Keytruda adjuvant NSCLC use in early-stage lung cancer
The FDA approved pembrolizumab (Keytruda) for adjuvant treatment after resection and platinum-based chemotherapy in stage IB, II, and IIIA NSCLC. The decision adds another regulatory catalyst for Merck and creates a useful tracking point for investors and BD teams watching pembrolizumab in lung cancer.
Revolution Medicines' Daraxonrasib: Pancreatic Cancer Breakthrough and Beyond
Daraxonrasib nearly doubled overall survival in a Phase III trial for pancreatic ductal adenocarcinoma, an unprecedented outcome. This article analyzes the clinical data, regulatory implications, and strategic impact for pharma BD and investors.